[go: up one dir, main page]

MA55205A - Formulations injectables prêtes à l'emploi - Google Patents

Formulations injectables prêtes à l'emploi

Info

Publication number
MA55205A
MA55205A MA055205A MA55205A MA55205A MA 55205 A MA55205 A MA 55205A MA 055205 A MA055205 A MA 055205A MA 55205 A MA55205 A MA 55205A MA 55205 A MA55205 A MA 55205A
Authority
MA
Morocco
Prior art keywords
ready
injectable formulations
use injectable
formulations
injectable
Prior art date
Application number
MA055205A
Other languages
English (en)
Inventor
Todd P Foster
Vijaya Bharti Joshi
Laibin Luo
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of MA55205A publication Critical patent/MA55205A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA055205A 2019-03-06 2020-03-05 Formulations injectables prêtes à l'emploi MA55205A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962814440P 2019-03-06 2019-03-06

Publications (1)

Publication Number Publication Date
MA55205A true MA55205A (fr) 2022-01-12

Family

ID=70009447

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055205A MA55205A (fr) 2019-03-06 2020-03-05 Formulations injectables prêtes à l'emploi

Country Status (13)

Country Link
US (1) US12295958B2 (fr)
EP (1) EP3934618A1 (fr)
JP (1) JP7323630B2 (fr)
KR (1) KR102671650B1 (fr)
AU (1) AU2020232306B2 (fr)
BR (1) BR112021017536A2 (fr)
CA (1) CA3132159C (fr)
IL (1) IL285520B2 (fr)
MA (1) MA55205A (fr)
MX (1) MX2021010689A (fr)
PH (1) PH12021551973A1 (fr)
WO (1) WO2020181024A1 (fr)
ZA (1) ZA202105883B (fr)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2557615C2 (de) 1975-12-20 1985-08-14 Bayer Ag, 5090 Leverkusen Neue Niclosamid-Suspensionsformulierungen
US5318781A (en) * 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
AU2001288323B2 (en) 2000-09-12 2006-11-23 Zoetis Services Llc Pharmaceutical composition having modified carrier
US6911441B2 (en) 2002-12-16 2005-06-28 Akzo Nobel N.V. Prolonged release pharmaceutical composition
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
CN1517090A (zh) 2003-01-20 2004-08-04 王玉万 含抗菌药物的兽用混悬注射剂或乳剂
US20040214753A1 (en) 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
CN1569000A (zh) * 2003-07-16 2005-01-26 王玉万 含头孢菌素的速效并长效注射剂
MX2011005217A (es) * 2008-11-19 2011-06-01 Merial Ltd Formulaciones que comprenden ceftiofur y cetoprofeno o ceftiofur y alcohol bencilico.
WO2012095438A1 (fr) 2011-01-12 2012-07-19 Intervet International B.V. Particules et suspensions d'antibiotiques céphalosporine
WO2013095166A1 (fr) * 2011-12-23 2013-06-27 Bayer New Zealand Limited Formulations antibiotiques
CA2865555C (fr) 2012-02-27 2021-01-12 Bayer New Zealand Limited Compositions a liberation controlee et leurs procedes d'utilisation
MY188825A (en) 2012-05-18 2022-01-06 Genentech Inc High-concentration monoclonal antibody formulations
PE20201150A1 (es) 2017-11-07 2020-10-26 Intervet Int Bv Composiciones farmaceuticas inyectables de isoxazolina y usos de las mismas
CN108578362A (zh) * 2018-05-30 2018-09-28 河北维尔利动物药业集团有限公司 一种头孢维星混悬注射液及其制备方法

Also Published As

Publication number Publication date
IL285520B1 (en) 2024-09-01
US20220125798A1 (en) 2022-04-28
JP2022523573A (ja) 2022-04-25
WO2020181024A1 (fr) 2020-09-10
IL285520A (en) 2021-09-30
JP7323630B2 (ja) 2023-08-08
KR102671650B1 (ko) 2024-06-04
AU2020232306B2 (en) 2023-11-16
KR20210120084A (ko) 2021-10-06
PH12021551973A1 (en) 2022-05-23
BR112021017536A2 (pt) 2021-11-09
ZA202105883B (en) 2023-03-29
MX2021010689A (es) 2021-10-01
CA3132159C (fr) 2023-11-21
AU2020232306A1 (en) 2021-09-02
IL285520B2 (en) 2025-01-01
EP3934618A1 (fr) 2022-01-12
US12295958B2 (en) 2025-05-13
NZ779449A (en) 2023-11-24
CA3132159A1 (fr) 2020-09-10

Similar Documents

Publication Publication Date Title
MA46696A (fr) Formulations injectables à dose unique prêtes à l'emploi
EP3400016A4 (fr) Formulations injectables à longue durée d'action
EP3989959A4 (fr) Formulations transdermiques
EP4125815A4 (fr) Compositions thérapeutiques
EP4043002A4 (fr) Composition dentaire
EP3823978A4 (fr) Compositions d'anticorps anti-fcrn
DK3725355T3 (da) Indpakket præcisionssmurt intermitterende urinkateter klar til brug
EP3820980A4 (fr) Compositions d'esterquats
MA53280A (fr) Composés utiles dans la thérapie du vih
EP4023292A4 (fr) Formulation d'injection
EP3864058A4 (fr) Composition photodurcissable
EP3917910A4 (fr) Composés et compositions thérapeutiques
EP3761952C0 (fr) Compositions topiques de soins de la peau
EP4044996C0 (fr) Composition d'hygiène buccale
EP4029491A4 (fr) Composition dentaire polymérisable
EP3974026A4 (fr) Composition destinée à améliorer la fonction hépatique
DK3911298T3 (da) Formuleringer
EP3793561A4 (fr) Composés médicamenteux antiviraux et composition associée
EP4044995C0 (fr) Compositions d'hygiène buccale
MA55205A (fr) Formulations injectables prêtes à l'emploi
EP3949952A4 (fr) Composition médicinale
EP3892256A4 (fr) Composition cosmétique
EP3813812A4 (fr) Dosage d'acétaminophène
DK3746047T3 (da) Injektionsbar sammensætning
EP3785548A4 (fr) Composition d'émulsion